CD19-targeted CAR T cells have shown impressive results in patients with relapsed or refractory B cell malignancies, leading to the approval of anti-CD19 CAR T cell therapy in patients with diffuse large B cell lymphoma and pediatric B-acute lymphocytic leukemia2,3. Here, CD19 is linked to diffuse large B-cell lymphoma.